Literature DB >> 21071501

Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience.

Peter Schellongowski1, Thomas Staudinger, Michael Kundi, Klaus Laczika, Gottfried J Locker, Andja Bojic, Oliver Robak, Valentin Fuhrmann, Ulrich Jäger, Peter Valent, Wolfgang R Sperr.   

Abstract

BACKGROUND: Acute myeloid leukemia is a life-threatening disease associated with high mortality rates. A substantial number of patients require intensive care. This investigation analyzes risk factors predicting admission to the intensive care unit in patients with acute myeloid leukemia eligible for induction chemotherapy, the outcome of these patients, and prognostic factors predicting their survival. DESIGN AND METHODS: A total of 406 consecutive patients with de novo acute myeloid leukemia (15-89 years) were analyzed retrospectively. Markers recorded at the time of diagnosis included karyotype, fibrinogen, C-reactive protein, and Charlson comorbidity index. In patients requiring critical care, the value of the Simplified Acute Physiology Score II, the need for mechanical ventilation, and vasopressor support were recorded at the time of intensive care unit admission. The independent prognostic relevance of the parameters was tested by multivariate analysis.
RESULTS: Sixty-two patients (15.3%) required intensive care, primarily due to respiratory failure (50.0%) or life-threatening bleeding (22.6%). Independent risk factors predicting intensive care unit admission were lower fibrinogen concentration, the presence of an infection, and comorbidity. The survival rate was 45%, with the Simplified Acute Physiology Score II being the only independent prognostic parameter (P<0.05). Survival was inferior in intensive care patients compared to patients not admitted to an intensive care unit. However, no difference between intensive care and non-intensive care patients was found concerning continuous complete remission at 6 years or survival at 6 years in patients who survived the first 30 days after diagnosis (non-intensive care patients: 28%; intensive care patients: 20%, P>0.05).
CONCLUSIONS: Ongoing infections, low fibrinogen and comorbidity are predictive for intensive care unit admission in acute myeloid leukemia. Although admission was a risk factor for survival, continuous complete remission and survival of patients alive at day 30 were similar in patients who were admitted or not admitted to an intensive care unit.

Entities:  

Mesh:

Year:  2010        PMID: 21071501      PMCID: PMC3031690          DOI: 10.3324/haematol.2010.031583

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  47 in total

Review 1.  Prognostic factors in acute myelogenous leukemia.

Authors:  E H Estey
Journal:  Leukemia       Date:  2001-04       Impact factor: 11.528

2.  Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit.

Authors:  T Staudinger; B Stoiser; M Müllner; G J Locker; K Laczika; S Knapp; H Burgmann; A Wilfing; J Kofler; F Thalhammer; M Frass
Journal:  Crit Care Med       Date:  2000-05       Impact factor: 7.598

3.  Outcomes of critically ill cancer patients in a university hospital setting.

Authors:  J P Kress; J Christenson; A S Pohlman; D R Linkin; J B Hall
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

4.  Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support.

Authors:  E Azoulay ; C Alberti ; C Bornstain ; G Leleu ; D Moreau ; C Recher ; S Chevret ; J R Le Gall ; L Brochard; B Schlemmer
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

5.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

Authors:  D Grimwade; H Walker; G Harrison; F Oliver; S Chatters; C J Harrison; K Wheatley; A K Burnett; A H Goldstone
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

Review 6.  Therapeutic options for acute myelogenous leukemia.

Authors:  E H Estey
Journal:  Cancer       Date:  2001-09-01       Impact factor: 6.860

7.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.

Authors:  M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

8.  Outcome and prognostic features of intensive care unit treatment in patients with hematological malignancies.

Authors:  Frank Kroschinsky; Matthias Weise; Thomas Illmer; Mathias Haenel; Martin Bornhaeuser; Gert Hoeffken; Gerhard Ehninger; Ulrich Schuler
Journal:  Intensive Care Med       Date:  2002-07-18       Impact factor: 17.440

9.  Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications?

Authors:  A Rabbat; D Chaoui; A Lefebvre; N Roche; O Legrand; C Lorut; B Rio; J-P Marie; G Huchon
Journal:  Leukemia       Date:  2008-04-24       Impact factor: 11.528

10.  Prognosis of hematologic malignancies does not predict intensive care unit mortality.

Authors:  Paul B Massion; Alain M Dive; Chantal Doyen; Pierre Bulpa; Jacques Jamart; André Bosly; Etienne Installé
Journal:  Crit Care Med       Date:  2002-10       Impact factor: 7.598

View more
  36 in total

Review 1.  [Hematological-oncological intensive care patients : Treatment without borders].

Authors:  M Kochanek; A Shimabukuro-Vornhagen; B Böll
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-02-06       Impact factor: 0.840

2.  Outcomes in critically ill chronic lymphocytic leukemia patients.

Authors:  Aliénor Xhaard; Loic Epelboin; David Schnell; François Vincent; Vincent Levy; Marion Malphettes; Elie Azoulay; Michaël Darmon
Journal:  Support Care Cancer       Date:  2013-02-15       Impact factor: 3.603

3.  Long-term prognosis of septic shock in cancer patients.

Authors:  Fabrice Camou; Marion Didier; Thibaut Leguay; Noël Milpied; Amaury Daste; Alain Ravaud; Gaëlle Mourissoux; Olivier Guisset; Nahéma Issa
Journal:  Support Care Cancer       Date:  2019-06-26       Impact factor: 3.603

Review 4.  The Intensive Care Medicine research agenda on critically ill oncology and hematology patients.

Authors:  Elie Azoulay; Peter Schellongowski; Michael Darmon; Philippe R Bauer; Dominique Benoit; Pieter Depuydt; Jigeeshu V Divatia; Virginie Lemiale; Maarten van Vliet; Anne-Pascale Meert; Djamel Mokart; Stephen M Pastores; Anders Perner; Frédéric Pène; Peter Pickkers; Kathryn A Puxty; Francois Vincent; Jorge Salluh; Ayman O Soubani; Massimo Antonelli; Thomas Staudinger; Michael von Bergwelt-Baildon; Marcio Soares
Journal:  Intensive Care Med       Date:  2017-07-19       Impact factor: 17.440

5.  Characteristics and outcomes of patients with hematologic malignancies receiving chemotherapy in the intensive care unit.

Authors:  Stephen M Pastores; Debra A Goldman; David J Shaz; Natalie Kostelecky; Ryan J Daley; Tim J Peterson; Kay See Tan; Neil A Halpern
Journal:  Cancer       Date:  2018-05-04       Impact factor: 6.860

Review 6.  [Chronic critically ill patients from the perspective of hematologists/oncologists].

Authors:  T Staudinger; P Schellongowski
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-02-28       Impact factor: 0.840

Review 7.  Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis.

Authors:  C Saillard; D Blaise; D Mokart
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

Review 8.  [Cancer patients in the intensive care unit. Goals of therapy, ethics, and palliation].

Authors:  P Schellongowski
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-03-21       Impact factor: 0.840

9.  Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit.

Authors:  Anna B Halpern; Eva Culakova; Roland B Walter; Gary H Lyman
Journal:  JAMA Oncol       Date:  2017-03-01       Impact factor: 31.777

10.  Trends in admission prevalence, illness severity and survival of haematological patients treated in Dutch intensive care units.

Authors:  Maarten van Vliet; Ilona W M Verburg; Mark van den Boogaard; Nicolette F de Keizer; Niels Peek; Nicole M A Blijlevens; Peter Pickkers
Journal:  Intensive Care Med       Date:  2014-06-28       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.